NCT04796324Phase 2Terminated

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Study sponsor: Allarity Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-01Actual
Enrollment · participants13Actual
Source updated2026-03-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 13 participants (actual).

Recruitment status changed

Before: Suspended. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview